The first patient is prescribed the Actiste[®] solution in Qatar
Brighter AB (“Brighter” or “The Company”) today announced that Actiste®, for the first time, is prescribed to a patient living with diabetes in Qatar.
Dr. Omar Mashhor at the Future Medical Center in Qatar who is the first physician in Qatar to prescribe the device is optimistic about Brighter’s offer, in terms of real-life data and other features.
“It’s a pleasure to start using Actiste® with my patients in Qatar and be one of the first prescribers in the country. As a strong believer in the impact of innovative technologies on patients' adherence and quality of life, I believe that Actiste® will provide healthcare professionals with very important real-life data, including the actual injected insulin dose, which is a unique feature of Actiste®. In the coming months I will work closely with Brighter to gain experience and explore all the benefits Actiste® can provide to my patients, to the health clinic I work for and to me as a treating physician and hopefully will be able publish its clinical impact on diabetes management”, says Omar Mashhor, Endocrinologist at Future Medical Center.
The first patient being prescribed the Actiste® device means that the first phase of Brighter’s commercialization in Qatar has been successful.
“This marks a big step in Brighter’s commercialization in the region and I am truly thankful for the commitment from both the medical professionals, our distributor and our staff. Their cooperation and support throughout the process has led us to yet another big milestone. Now, our continued efforts in Qatar are primarily on sales”, says Brighter CEO Erik Lissner.
The company is also working closely with its distributor who, once validation of the product is done, will be able to take part in public procurement bids.
For further information, please contact:
Investor Relations
ir@brighter.se
Certified Adviser
Brighter’s Certified Adviser är Mangold Fondkommission AB,
+46 8 5277 5020, ca@mangold.se, www.mangold.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.